SOHO 2022 | Monoclonal antibodies in AML – current and future outlooks
Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the promise of using monoclonal antibodies (mAbs) for the treatment of acute myeloid leukemia (AML). Dr Fathi first comments on the promise of combining magrolimab with azacitidine, and then goes on to explain where various antibodies and combinations may fit in the AML treatment armamentarium. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum
